Anil Dangi1,2, Xunrong Luo1,2,3. 1. Center for Kidney Research and Therapeutics, Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, United States. 2. Division of Nephrology and Hypertension, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States. 3. Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Abstract
PURPOSE OF REVIEW: The use of donor apoptotic cells is an emerging therapy for inducing transplantation tolerance. In this review, we will discuss current understanding of mechanisms of this approach, as well as crucial aspects necessary for successful translation of this approach to clinical transplantation. RECENT FINDINGS: Transplantation tolerance by donor apoptotic cells is mediated by their homeostatic interaction with recipient phagocytes, and subsequent expansion of suppressor cell populations as well as inhibition of effector T cells via deletion and anergy. To ensure their tolerogenicity, it is critical to procure non-stressed donor cells, and to induce and arrest their apoptosis at the appropriate stage prior to their administration. Equally important is the monitoring of dynamics of recipient immunological status, and its influences on tolerance efficacy and longevity. Emerging concepts and technologies may significantly streamline tolerogen manufacture and delivery of this approach, and smooth its transition to clinical application. SUMMARY: Hijacking homeostatic clearance of donor apoptotic cells is a promising strategy for transplantation tolerance. Timing is now mature for concerted efforts for transitioning this strategy to clinical transplantation.
PURPOSE OF REVIEW: The use of donor apoptotic cells is an emerging therapy for inducing transplantation tolerance. In this review, we will discuss current understanding of mechanisms of this approach, as well as crucial aspects necessary for successful translation of this approach to clinical transplantation. RECENT FINDINGS: Transplantation tolerance by donor apoptotic cells is mediated by their homeostatic interaction with recipient phagocytes, and subsequent expansion of suppressor cell populations as well as inhibition of effector T cells via deletion and anergy. To ensure their tolerogenicity, it is critical to procure non-stressed donor cells, and to induce and arrest their apoptosis at the appropriate stage prior to their administration. Equally important is the monitoring of dynamics of recipient immunological status, and its influences on tolerance efficacy and longevity. Emerging concepts and technologies may significantly streamline tolerogen manufacture and delivery of this approach, and smooth its transition to clinical application. SUMMARY: Hijacking homeostatic clearance of donor apoptotic cells is a promising strategy for transplantation tolerance. Timing is now mature for concerted efforts for transitioning this strategy to clinical transplantation.
Authors: Z Wang; A T Larregina; W J Shufesky; M J Perone; A Montecalvo; A F Zahorchak; A W Thomson; A E Morelli Journal: Am J Transplant Date: 2006-06 Impact factor: 8.086
Authors: F Bonnefoy; E Masson; S Perruche; A Marandin; C Borg; A Radlovic; B Shipman; P Tiberghien; P Saas; F Kleinclauss Journal: Leukemia Date: 2007-12-06 Impact factor: 11.528
Authors: Z Solhjou; M Uehara; B Bahmani; O H Maarouf; T Ichimura; C R Brooks; W Xu; M Yilmaz; A Elkhal; S G Tullius; I Guleria; M M McGrath; R Abdi Journal: Am J Transplant Date: 2017-04-18 Impact factor: 8.086
Authors: Reid A Roberts; Timothy K Eitas; James D Byrne; Brandon M Johnson; Patrick J Short; Karen P McKinnon; Shannon Reisdorf; J Christopher Luft; Joseph M DeSimone; Jenny P Ting Journal: Biomaterials Date: 2015-08-20 Impact factor: 12.479
Authors: Tatsuo Kawai; A Benedict Cosimi; Thomas R Spitzer; Nina Tolkoff-Rubin; Manikkam Suthanthiran; Susan L Saidman; Juanita Shaffer; Frederic I Preffer; Ruchuang Ding; Vijay Sharma; Jay A Fishman; Bimalangshu Dey; Dicken S C Ko; Martin Hertl; Nelson B Goes; Waichi Wong; Winfred W Williams; Robert B Colvin; Megan Sykes; David H Sachs Journal: N Engl J Med Date: 2008-01-24 Impact factor: 91.245
Authors: Joseph R Leventhal; James M Mathew; Daniel R Salomon; Sunil M Kurian; Manikkam Suthanthiran; Anat Tambur; John Friedewald; Lorenzo Gallon; Jane Charette; Josh Levitsky; Yashpal Kanwar; Michael Abecassis; Joshua Miller Journal: J Am Soc Nephrol Date: 2013-06-20 Impact factor: 10.121
Authors: Shusen Wang; James Tasch; Taba Kheradmand; Jodie Ulaszek; Sora Ely; Xiaomin Zhang; Bernhard J Hering; Stephen D Miller; Xunrong Luo Journal: Diabetes Date: 2013-07-12 Impact factor: 9.461